MCID: NRC002
MIFTS: 64

Narcolepsy

Categories: Rare diseases, Neuronal diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 72 49 24 50 36 51 41 14 69 59
Narcolepsy-Cataplexy Syndrome 49 55 69
Narcoleptic Syndrome 49 24
Gelineau Syndrome 49 24
Paroxysmal Sleep 12 49
Narcolepsy, Without Cataplexy 12
Narcolepsy Without Cataplexy 55
Cataplexy and Narcolepsy 28
Gelineau's Syndrome 49
Gélineau Disease 55

Characteristics:

Orphanet epidemiological data:

55
narcolepsy-cataplexy syndrome
Prevalence: 1-5/10000 (Europe),1-5/10000 (Norway),1-5/10000 (Finland),1-5/10000 (China); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;
narcolepsy without cataplexy
Prevalence: 1-5/10000 (United States); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:8986
ICD9CM 34 347.0
MeSH 41 D009290
NCIt 46 C84489
UMLS via Orphanet 70 C0751362 C0027404
MESH via Orphanet 42 D009290
ICD10 via Orphanet 33 G47.4
KEGG 36 H01293

Summaries for Narcolepsy

NINDS : 50 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleeep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience irresistable bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis . The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to cerebellar ataxia, deafness, and narcolepsy, autosomal dominant and idiopathic hypersomnia, and has symptoms including abnormality of vision, hallucinations and syncope. An important gene associated with Narcolepsy is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways are HTLV-I infection and Toxoplasmosis. The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference : 24 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases : 49 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial. There is no cure, but some symptoms can be managed with medicines and lifestyle changes. Last updated: 4/27/2015

PubMed Health : 59
About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness.Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity.Narcolepsy also can cause:

Wikipedia : 72 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 34.8 DNMT1 HCRT
2 idiopathic hypersomnia 33.4 HCRT HLA-DQB1
3 hypersomnia 33.2 HCRT HCRTR1 HLA-DQB1 HLA-DRB1
4 sleep disorder 33.1 HCRT HCRTR1 HCRTR2 MOG
5 neuromyelitis optica 30.8 HCRT HLA-DRB1 MOG
6 acute disseminated encephalomyelitis 30.6 HCRT HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
7 celiac disease 1 30.3 HLA-DQA1 HLA-DQB1 TNF
8 narcolepsy 1 12.4
9 narcolepsy 7 12.3
10 narcolepsy 2 12.1
11 narcolepsy 4 12.0
12 narcolepsy 5 12.0
13 narcolepsy 3 12.0
14 narcolepsy 6 12.0
15 disseminated sclerosis with narcolepsy 11.8
16 limbic encephalitis with lgi1 antibodies 10.8 HLA-DQB1 HLA-DRB1
17 pediatric multiple sclerosis 10.8 HLA-DQB1 HLA-DRB1 MOG
18 chronic beryllium disease 10.8 HLA-DQB1 HLA-DRB1 TNF
19 rohhad 10.8 HCRT HCRTR1 HCRTR2
20 autoimmune pancreatitis 10.8 HLA-DQB1 HLA-DRB1 TNF
21 achalasia, familial esophageal 10.8 HLA-DQA1 HLA-DQB1
22 focal epithelial hyperplasia 10.8 HLA-DQA1 HLA-DQB1 HLA-DRB1
23 lichen sclerosus 10.8 HLA-DQB1 HLA-DRB1 TNF
24 recurrent respiratory papillomatosis 10.8 HLA-DQA1 HLA-DQB1 HLA-DRB1
25 microscopic colitis 10.8 HLA-DQB1 HLA-DRB1 TNF
26 endometritis 10.8 HLA-DQA1 HLA-DQB1 TNF
27 sympathetic ophthalmia 10.8 HLA-DQA1 HLA-DRB1 TNF
28 idiopathic bronchiectasis 10.8 HLA-DQA1 HLA-DQB1 HLA-DRB1
29 panuveitis 10.8 HLA-DQB1 HLA-DRB1 TNF
30 beryllium disease 10.8 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
31 oligoarticular juvenile idiopathic arthritis 10.8 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
32 geographic tongue 10.8 HLA-DQB1 HLA-DRB1 TNF
33 severe hemophilia a 10.8 HLA-DQB1 HLA-DRB1 TNF
34 guillain-barre syndrome 10.8 HCRT HLA-DQB1 TNF
35 recurrent hypersomnia 10.8 HCRT HLA-DQB1
36 optic neuritis 10.8 HLA-DRB1 MOG TNF
37 metal allergy 10.8 HLA-DQB1 HLA-DRB1
38 rheumatic heart disease 10.8 HLA-DQA1 HLA-DRB1 TNF
39 rubella 10.8 HLA-DRB1 MOG TNF
40 toxoplasmosis 10.8 HLA-DQA1 HLA-DQB1 TNF
41 central nervous system disease 10.7 ATXN3 HCRT MOG TNF
42 lichen planopilaris 10.7 HLA-DQB1 HLA-DRB1
43 graft-versus-host disease 10.7 HLA-DQB1 HLA-DRB1 TNF
44 microscopic polyangiitis 10.7 HLA-DRB1 TNF
45 autoimmune disease 10.7 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG TNF
46 type ii mixed cryoglobulinemia 10.7 HLA-DQB1 HLA-DRB1
47 juvenile rheumatoid arthritis 10.7 HLA-DQA1 HLA-DRB1 TNF
48 idiopathic inflammatory myopathy 10.7 HLA-DQB1 HLA-DRB1
49 hallucinogen dependence 10.7 HCRTR1 HCRTR2
50 leishmaniasis 10.7 HLA-DQA1 HLA-DRB1 TNF

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

Human phenotypes related to Narcolepsy:

55 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of vision 55 31 frequent (33%) Frequent (79-30%) HP:0000504
2 hallucinations 55 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0000738
3 syncope 55 31 occasional (7.5%) Occasional (29-5%) HP:0001279
4 slurred speech 55 31 occasional (7.5%) Occasional (29-5%) HP:0001350
5 obesity 55 31 occasional (7.5%) Occasional (29-5%) HP:0001513
6 excessive daytime sleepiness 55 31 hallmark (90%) Very frequent (99-80%) HP:0002189
7 abnormal rapid eye movement sleep 55 31 frequent (33%) Frequent (79-30%) HP:0002494
8 cataplexy 55 31 hallmark (90%) Very frequent (99-80%) HP:0002524
9 transient global amnesia 55 31 hallmark (90%) Very frequent (99-80%) HP:0010534
10 excessive daytime somnolence 55 31 hallmark (90%) Very frequent (99-80%) HP:0001262
11 insomnia 55 31 hallmark (90%) Very frequent (99-80%) HP:0100785
12 abnormality of the eye 55 Frequent (79-30%)
13 sleep disturbance 55 Very frequent (99-80%),Very frequent (99-80%)
14 behavioral abnormality 55 Occasional (29-5%)

UMLS symptoms related to Narcolepsy:


sluggishness, sleeplessness, excessive daytime somnolence, snoring, sleep disturbances, hemiplegia

Drugs & Therapeutics for Narcolepsy

PubMedHealth treatment related to Narcolepsy: 59

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are.Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment.

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
3
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Sodium oxybate Approved Phase 4,Phase 3,Phase 2,Phase 1 502-85-2 5360545
6
Rasagiline Approved Phase 4 136236-51-6 3052776
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
9 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
11 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
15 calcium channel blockers Phase 4
16 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Phase 1
17 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Tranquilizing Agents Phase 4
19 Vaccines Phase 4
20 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
21 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1
22 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
23 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Anti-Anxiety Agents Phase 4
25 Anticonvulsants Phase 4
26 Pharmaceutical Solutions Phase 4,Phase 3
27 Antimanic Agents Phase 4
28 Excitatory Amino Acid Antagonists Phase 4
29 Excitatory Amino Acids Phase 4
30 Protective Agents Phase 4,Phase 1,Phase 2
31 Psychotropic Drugs Phase 4
32 Autonomic Agents Phase 4,Phase 2,Phase 1
33 Antiparkinson Agents Phase 4
34 Calcium, Dietary Phase 4,Phase 1,Phase 2
35 interferons Phase 4
36 Dopamine agonists Phase 4
37 Monoamine Oxidase Inhibitors Phase 4
38 Neuroprotective Agents Phase 4
39 Interferon-alpha Phase 4
40 Antioxidants Phase 4
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
43
Methylphenidate Approved, Investigational Phase 2, Phase 3 20748-11-2, 113-45-1 4158
44
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
45
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
47 Narcotics Phase 3
48 Analgesics, Opioid Phase 3
49
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 102)

# Name Status NCT ID Phase Drugs
1 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
2 Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription Completed NCT00244465 Phase 4
3 Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS Completed NCT00118378 Phase 4 Modafinil;Placebo
4 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
5 Pain Expectations in Subjects With Osteoarthritis Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
6 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
7 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
8 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997 Phase 4
9 Xyrem and Brain Dopamine in Narcolepsy Recruiting NCT02637076 Phase 4 Xyrem
10 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4 modafinil
11 Armodafinil for Patients Starting Hepatitis C Virus Treatment Terminated NCT01470651 Phase 4 Armodafinil;Sugar Pill
12 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4 Rasagiline;Pramipexole
13 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
14 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
15 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
16 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
17 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
18 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
19 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
20 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
21 Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Completed NCT01399606 Phase 3 BF2.649
22 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
23 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
24 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
25 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
26 Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients Completed NCT00049803 Phase 3 sodium oxybate
27 Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
28 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
29 Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
30 Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Completed NCT01789398 Phase 3 BF2.649
31 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Completed NCT01800045 Phase 3 Pitolisant;Placebo
32 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3 Methylphenidate;Placebo
33 Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3 Nuvigil;Placebo
34 Modafinil in Cancer Related Fatigue Completed NCT01440621 Phase 3 Modafinil;Pyridoxine
35 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
36 Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Recruiting NCT02720744 Phase 3 Sodium Oxybate;Placebo
37 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Recruiting NCT03030599 Phase 3 JZP-258
38 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT02221869 Phase 3 Xyrem
39 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
40 A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Completed NCT00424931 Phase 2 JNJ-17216498;JNJ-17216498;Modafinil
41 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
42 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
43 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
44 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
45 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2 Flumazenil
46 Methylphenidate and Parkinson's Disease Completed NCT00359723 Phase 2 methylphenidate
47 Sodium Oxybate in Schizophrenia With Insomnia Completed NCT00594256 Phase 2 Sodium Oxybate
48 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
49 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence Completed NCT00469508 Phase 2 Modafinil;Placebo
50 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Genetic tests related to Narcolepsy:

# Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy 28

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

38
Brain, Eye, Testes, Heart, T Cells, Amygdala, Skin

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 869)
# Title Authors Year
1
Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. ( 29449194 )
2018
2
An Epigenome-wide Association Study of DNA Methylation and An Integrated Genetic and Epigenetic Approach for Narcolepsy. ( 29425374 )
2018
3
Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. ( 29195824 )
2018
4
Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. ( 29321233 )
2018
5
Anesthetic Management of Narcolepsy Patients During Surgery: A Systematic Review. ( 29257771 )
2018
6
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
7
Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy. ( 29351827 )
2018
8
The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. ( 29198301 )
2018
9
The Immune Basis ofA Narcolepsy: What Is the Evidence? ( 28778227 )
2017
10
Prevalence of nocturnal sleep onset rapid movement sleep period (SOREMP) in narcolepsy type 1 and type 2. ( 28889987 )
2017
11
Narcolepsy susceptibility gene CCR3 modulates sleep-wake patterns in mice. ( 29186205 )
2017
12
Sleep-wake stability in narcolepsy patients with normal, low and unmeasurable hypocretin levels. ( 28522076 )
2017
13
Effective treatment of narcolepsy-like symptoms with high-frequency repetitive transcranial magnetic stimulation: A case report. ( 29145290 )
2017
14
Adenotonsillectomy outcomes in children with sleep apnea and narcolepsy. ( 28802388 )
2017
15
Association Study of HLA-DQB1*0602 Allele in Iranian Patients with Narcolepsy. ( 29149785 )
2017
16
Sleepiness in Narcolepsy. ( 28778231 )
2017
17
Irish MP calls for key documents on Pandemrix to be handed to lawyers representing children with narcolepsy. ( 28428181 )
2017
18
Narcolepsy in Saudi patients before and after the 2009 H1N1 vaccination. The experience of 2 referral centers. ( 29209667 )
2017
19
Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( 28364477 )
2017
20
Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. ( 28449892 )
2017
21
Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported measures. ( 28366326 )
2017
22
Update on the treatment of narcolepsy: clinical efficacy of pitolisant. ( 28490912 )
2017
23
Spectral electroencephalography profile of rapid eye movement sleep at sleep onset in narcolepsy type 1. ( 27905666 )
2017
24
Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. ( 28940143 )
2017
25
Is there a relationship between narcolepsy, multiple sclerosis and HLA-DQB1*06:02? ( 28658402 )
2017
26
Pituitary Macrotumor Causing Narcolepsy-Cataplexy in a Dachshund. ( 28090682 )
2017
27
Spontaneous reporting of suspected narcolepsy after vaccination against pandemic influenza A (H1N1) in Germany. ( 28809087 )
2017
28
New developments in the management of narcolepsy. ( 28424564 )
2017
29
Narcolepsy drug could help food addicts lose weight. ( 28075285 )
2017
30
Correlates to Problem Behaviors in Pediatric Narcolepsy: A Pilot Study. ( 29117887 )
2017
31
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
32
Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. ( 28796576 )
2017
33
Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. ( 28860883 )
2017
34
Nocturnal Dynamics of Sleep-Wake Transitions in Patients With Narcolepsy. ( 28364512 )
2017
35
Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. ( 28302408 )
2017
36
Sleep-wake patterns, non-rapid eye movement, and rapid eye movement sleep cycles in teenage narcolepsy. ( 28449905 )
2017
37
Quality of life and trust among young people with narcolepsy and their families, after the PandemrixAr vaccination: protocol for a case-control study. ( 28835221 )
2017
38
[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. ( 28775709 )
2017
39
a91Pitolisant for narcolepsy. ( 28087755 )
2017
40
Criteria for gauging response to sodium oxybate for narcolepsy. ( 29205601 )
2017
41
Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. ( 28847694 )
2017
42
Narcolepsy and Other Central Hypersomnias. ( 28777172 )
2017
43
Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy. ( 28840177 )
2017
44
Sleep spindle density in narcolepsy. ( 28522097 )
2017
45
Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. ( 28364500 )
2017
46
Migraine and risk of narcolepsy in children: A nationwide longitudinal study. ( 29216286 )
2017
47
The relationship between orexin levels and blood pressure changes in patients with narcolepsy. ( 29023559 )
2017
48
Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. ( 28522102 )
2017
49
Investigational therapies for the treatment of narcolepsy. ( 28726523 )
2017
50
Cortical and Subcortical Brain Changes in Children and Adolescents With Narcolepsy Type 1. ( 29244164 )
2017

Variations for Narcolepsy

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF TNFSF4
2 chemical synaptic transmission GO:0007268 9.78 ATXN3 HCRT HCRTR1 HCRTR2
3 neuropeptide signaling pathway GO:0007218 9.7 HCRT HCRTR1 HCRTR2
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.69 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 T cell costimulation GO:0031295 9.63 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.58 HCRT HCRTR2 P2RY11
8 response to peptide GO:1901652 9.54 HCRTR1 HCRTR2
9 feeding behavior GO:0007631 9.43 HCRT HCRTR1 HCRTR2
10 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.37 HCRTR1 HCRTR2
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.32 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
14 antigen processing and presentation GO:0019882 8.92 CTSH HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 orexin receptor activity GO:0016499 8.96 HCRTR1 HCRTR2
3 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....